Avalon GloboCare Corp. announced that the Company has signed a memorandum of understanding with Lu Daopei Hematology Institute to co-develop precision companion diagnostics (CDx) for chimeric antigen receptor (CAR)-T cell therapies. To further strengthen its CDx development capabilities, Avalon has appointed Dr. Hongxing Liu, M.D., M.S., Executive President of LDHI and a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2713 USD | -8.03% | -7.78% | -43.83% |
22/04 | Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference | CI |
17/04 | North American Morning Briefing : Stock Futures -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
-43.83% | 3.28M | |
-22.32% | 7.83B | |
+0.14% | 2.58B | |
-8.23% | 2.48B | |
-40.47% | 2.46B | |
-14.15% | 1.84B | |
-20.84% | 1.53B | |
-42.17% | 1.22B | |
+16.01% | 1.2B | |
+14.92% | 961M |
- Stock Market
- Equities
- ALBT Stock
- News Avalon GloboCare Corp.
- Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board